Segmentectomy for cancer control in radiologically pure-solid clinical stage IA3 lung cancer.
Lobectomy
Non-small-cell lung cancer
Pure-solid
Recurrence
Segmentectomy
Journal
Interdisciplinary cardiovascular and thoracic surgery
ISSN: 2753-670X
Titre abrégé: Interdiscip Cardiovasc Thorac Surg
Pays: England
ID NLM: 9918540787006676
Informations de publication
Date de publication:
02 Sep 2023
02 Sep 2023
Historique:
received:
20
04
2023
revised:
10
07
2023
accepted:
16
08
2023
medline:
17
8
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
ppublish
Résumé
This study aimed to compare cancer control after segmentectomy and lobectomy in patients with radiologically pure-solid clinical stage IA3 non-small-cell lung cancer (NSCLC). Patients with radiologically pure-solid clinical stage IA3 NSCLC who underwent lobectomy or segmentectomy at 3 institutions between 2010 and 2019 were identified. We estimated propensity scores to adjust for confounding variables regarding tumour malignancy, including age, sex, smoking history, tumour size, maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography, lymph node dissection, histological type and lymphatic, vascular and pleural invasion. Cumulative incidence of recurrence (CIR) was evaluated as a primary end point. Among 412 patients, postoperative recurrence occurred in 7 of 44 patients (15.9%) undergoing segmentectomy, and 71 of 368 patients (19.3%) undergoing lobectomy. CIR was comparable between patients undergoing segmentectomy (5-year rate, 21.9%) and those undergoing lobectomy (5-year rate, 20.8%; P = 0.88). Locoregional recurrence did not differ between patients undergoing segmentectomy (6.8%) and those undergoing lobectomy (9.0%). In multivariable analysis, segmentectomy (versus lobectomy) was not identified as an independent prognostic factor for CIR (hazard ratio, 1.045; 95% confidence interval, 0.475-2.298; P = 0.91). In propensity score matching of 40 pairs, CIR was not significantly different between patients undergoing segmentectomy (5-year rate, 20.7%) and those undergoing lobectomy (5-year rate, 18.4%; P = 0.81). Cancer control may be comparable between segmentectomy and lobectomy in patients with radiologically pure-solid clinical stage IA3 NSCLC. Further studies are warranted to clarify the survival benefits of segmentectomy in these patients.
Identifiants
pubmed: 37589650
pii: 7244022
doi: 10.1093/icvts/ivad138
pmc: PMC10533752
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.
Références
Eur J Cardiothorac Surg. 2022 Jun 15;62(1):
pubmed: 35678584
J Thorac Cardiovasc Surg. 2021 May;161(5):1639-1648.e2
pubmed: 32331817
N Engl J Med. 2023 Feb 9;388(6):489-498
pubmed: 36780674
J Thorac Cardiovasc Surg. 2022 Mar;163(3):791-801.e4
pubmed: 33516459
Eur J Cardiothorac Surg. 2022 Jul 11;62(2):
pubmed: 35150248
Eur J Cardiothorac Surg. 2020 Dec 1;58(6):1245-1253
pubmed: 32893296
Ann Thorac Surg. 2018 May;105(5):1483-1491
pubmed: 29462591
Lancet Respir Med. 2023 Jun;11(6):540-549
pubmed: 36893780
Eur J Cardiothorac Surg. 2022 Dec 2;63(1):
pubmed: 36321968
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Ann Thorac Surg. 2021 Sep;112(3):935-943
pubmed: 33144104
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
J Thorac Cardiovasc Surg. 2013 Jul;146(1):17-23
pubmed: 23246051
J Thorac Cardiovasc Surg. 2011 Jun;141(6):1384-91
pubmed: 21440264
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Eur J Cardiothorac Surg. 2023 Feb 3;63(2):
pubmed: 36692163
Eur Respir J. 2019 May 9;53(5):
pubmed: 30819811
J Thorac Cardiovasc Surg. 2021 Apr;161(4):1469-1480
pubmed: 32451073
Ann Thorac Surg. 2019 May;107(5):1500-1506
pubmed: 30579848
Surg Today. 2021 Jul;51(7):1188-1202
pubmed: 33745094
J Thorac Cardiovasc Surg. 2005 Jan;129(1):87-93
pubmed: 15632829
Interact Cardiovasc Thorac Surg. 2022 Nov 8;35(6):
pubmed: 36161317
Eur J Cardiothorac Surg. 2022 Aug 3;62(3):
pubmed: 35293580
Ann Thorac Surg. 2022 Sep;114(3):959-967
pubmed: 35181271
Ann Thorac Surg. 2007 Sep;84(3):926-32; discussion 932-3
pubmed: 17720401
Clin Lung Cancer. 2020 Nov;21(6):e528-e538
pubmed: 32482526
Eur J Cardiothorac Surg. 2023 Feb 3;63(2):
pubmed: 36571485
Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3
pubmed: 7677489
J Thorac Cardiovasc Surg. 2014 Oct;148(4):1186-1192.e3
pubmed: 24746994
Lancet. 2022 Apr 23;399(10335):1607-1617
pubmed: 35461558